FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3077251618> ?p ?o ?g. }

• W3077251618 endingPage "175883592094092" @default.
• W3077251618 startingPage "175883592094092" @default.
• W3077251618 abstract "Immune checkpoint inhibitors (ICIs) have shown encouraging treatment efficacy for metastatic breast cancer in several clinical trials. However, response only occurred in a small population. Evidence predicting response and survival of patients with metastatic breast cancer following ICI treatment with existing biomarkers has not been well summarized. This review aimed to summarize the efficacy and predictive factors of immune checkpoint therapy in metastatic breast cancer, which is critical for clinical practice.PubMed, Embase, Cochrane Library, Web of Science, www.clinicaltrials.gov, and meeting abstracts were comprehensively searched to identify clinical trials. The outcomes were objective response rate (ORR), treatment-related adverse events (trAEs), immune-related adverse events (irAEs), progression-free survival (PFS), and overall survival (OS).In this review, 27 studies with 1746 patients were included for quantitative synthesis. The pooled ORR was 19% [95% confidence interval (CI) = 12-27%]. Programmed death-ligand 1 (PD-L1)-positive patients had a higher response rate [odds ratio (OR) = 1.44, p = 0.01]. First-line immunotherapy had a better ORR than second-line immunotherapy (OR = 2.00, p = 0.02). Tumor-infiltrating lymphocytes (TILs) ⩾5% (OR = 2.53, p = 0.002) and high infiltrated CD8+ T-cell level (OR = 4.33, p = 0.006) were ideal predictors of immune checkpoint therapy response. Liver metastasis indicated poor response (OR = 0.19, p = 0.009). However, the difference was non-significant in ORR based on age, performance status score, lymph node metastasis, and lactate dehydrogenase (LDH) level. In addition, the PD-L1-positive subgroup had a better 1-year PFS (OR = 1.55, p = 0.04) and 2-year OS (OR = 2.28, p = 0.02) following ICI treatment. The pooled incidence during ICI therapy of grade 3-4 trAEs was 25% (95% CI = 16-34%), whereas for grade 3-4 irAEs it was 15% (95% CI = 11-19%).Metastatic breast cancer had modest response to ICI therapy. PD-L1-positive, first-line immunotherapy, non-liver metastasis, and high TIL and CD8+ T-cell infiltrating levels could predict better response to ICI treatment. Patients with PD-L1-positive tumor could gain more survival benefits from immune checkpoint therapy." @default.
• W3077251618 created "2020-08-24" @default.
• W3077251618 creator A5018814025 @default.
• W3077251618 creator A5026279705 @default.
• W3077251618 creator A5048093999 @default.
• W3077251618 creator A5057676647 @default.
• W3077251618 creator A5069651421 @default.
• W3077251618 creator A5078526337 @default.
• W3077251618 date "2020-01-01" @default.
• W3077251618 modified "2023-09-30" @default.
• W3077251618 title "Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis" @default.
• W3077251618 cites W1573433003 @default.
• W3077251618 cites W1896351481 @default.
• W3077251618 cites W1978993716 @default.
• W3077251618 cites W2008451487 @default.
• W3077251618 cites W2009519656 @default.
• W3077251618 cites W2017044005 @default.
• W3077251618 cites W2039123767 @default.
• W3077251618 cites W2057187391 @default.
• W3077251618 cites W2060070314 @default.
• W3077251618 cites W2062030781 @default.
• W3077251618 cites W2082977560 @default.
• W3077251618 cites W2097995306 @default.
• W3077251618 cites W2100413206 @default.
• W3077251618 cites W2116760308 @default.
• W3077251618 cites W2124427232 @default.
• W3077251618 cites W2134833483 @default.
• W3077251618 cites W2135707184 @default.
• W3077251618 cites W2152027636 @default.
• W3077251618 cites W2156222101 @default.
• W3077251618 cites W2157823046 @default.
• W3077251618 cites W2343453190 @default.
• W3077251618 cites W2345415641 @default.
• W3077251618 cites W2466558384 @default.
• W3077251618 cites W2504940557 @default.
• W3077251618 cites W2560367415 @default.
• W3077251618 cites W2570878489 @default.
• W3077251618 cites W2585122966 @default.
• W3077251618 cites W2606495925 @default.
• W3077251618 cites W2607272476 @default.
• W3077251618 cites W2621755511 @default.
• W3077251618 cites W2623028642 @default.
• W3077251618 cites W2761851330 @default.
• W3077251618 cites W2766673799 @default.
• W3077251618 cites W2775220577 @default.
• W3077251618 cites W2791308824 @default.
• W3077251618 cites W2798022026 @default.
• W3077251618 cites W2799386807 @default.
• W3077251618 cites W2806941772 @default.
• W3077251618 cites W2885139325 @default.
• W3077251618 cites W2888024151 @default.
• W3077251618 cites W2889646458 @default.
• W3077251618 cites W2889746019 @default.
• W3077251618 cites W2897422388 @default.
• W3077251618 cites W2897523860 @default.
• W3077251618 cites W2901050567 @default.
• W3077251618 cites W2902530914 @default.
• W3077251618 cites W2902655481 @default.
• W3077251618 cites W2903875264 @default.
• W3077251618 cites W2906250995 @default.
• W3077251618 cites W2911188335 @default.
• W3077251618 cites W2912761459 @default.
• W3077251618 cites W2914356810 @default.
• W3077251618 cites W2914643394 @default.
• W3077251618 cites W2939093246 @default.
• W3077251618 cites W2944687997 @default.
• W3077251618 cites W2944914845 @default.
• W3077251618 cites W2946703956 @default.
• W3077251618 cites W2950563001 @default.
• W3077251618 cites W2953287793 @default.
• W3077251618 cites W2954874542 @default.
• W3077251618 cites W2961514353 @default.
• W3077251618 cites W2961686530 @default.
• W3077251618 cites W2966740586 @default.
• W3077251618 cites W2992834767 @default.
• W3077251618 cites W3015740705 @default.
• W3077251618 doi "https://doi.org/10.1177/1758835920940928" @default.
• W3077251618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7436841" @default.
• W3077251618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32874208" @default.
• W3077251618 hasPublicationYear "2020" @default.
• W3077251618 type Work @default.
• W3077251618 sameAs 3077251618 @default.
• W3077251618 citedByCount "76" @default.
• W3077251618 countsByYear W30772516182021 @default.
• W3077251618 countsByYear W30772516182022 @default.
• W3077251618 countsByYear W30772516182023 @default.
• W3077251618 crossrefType "journal-article" @default.
• W3077251618 hasAuthorship W3077251618A5018814025 @default.
• W3077251618 hasAuthorship W3077251618A5026279705 @default.
• W3077251618 hasAuthorship W3077251618A5048093999 @default.
• W3077251618 hasAuthorship W3077251618A5057676647 @default.
• W3077251618 hasAuthorship W3077251618A5069651421 @default.
• W3077251618 hasAuthorship W3077251618A5078526337 @default.
• W3077251618 hasBestOaLocation W30772516181 @default.
• W3077251618 hasConcept C121608353 @default.
• W3077251618 hasConcept C126322002 @default.
• W3077251618 hasConcept C143998085 @default.
• W3077251618 hasConcept C197934379 @default.

• next